LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・Certara Inc

Certara Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.11 9.42

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.58

Max

5.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.9M -8.8M
Pardavimai	3.3M 107M
P/E Sektoriaus vid.	100.714 49.701
Pelnas, tenkantis vienai akcijai	0.09
Pelno marža	-8.196
Darbuotojai	1,515
EBITDA	-8.9M 23M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+75.6% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-89M 709M
Ankstesnė atidarymo kaina	-4.31
Ankstesnė uždarymo kaina	5.11

Naujienos nuotaikos

By Acuity

50%

159 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

11.27 / 12.79 Palaikymas ir pasipriešinimas

Certara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-20 23:31; UTC

Karštos akcijos

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026-05-20 22:52; UTC

Pagrindinės rinkos jėgos

Osisko Shares Fall on Planned Convertible Notes Offering

2026-05-20 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-20 23:44; UTC

Uždarbis

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026-05-20 23:35; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026-05-20 23:30; UTC

Rinkos pokalbiai

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026-05-20 23:15; UTC

Rinkos pokalbiai

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026-05-20 23:14; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026-05-20 23:02; UTC

Rinkos pokalbiai

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 22:27; UTC

Rinkos pokalbiai

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026-05-20 22:14; UTC

Rinkos pokalbiai

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026-05-20 22:10; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026-05-20 22:00; UTC

Uždarbis

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026-05-20 21:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026-05-20 21:27; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026-05-20 21:20; UTC

Uždarbis

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026-05-20 21:19; UTC

Uždarbis

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026-05-20 21:18; UTC

Uždarbis

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026-05-20 21:17; UTC

Uždarbis

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026-05-20 21:16; UTC

Uždarbis

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Certara Inc Prognozė

Kainos tikslas

By TipRanks

75.6% į viršų

12 mėnesių prognozė

Vidutinis 8.06 USD 75.6%

Aukščiausias 10 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Certara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Certara Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

11.27 / 12.79Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

159 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.